Lysis of primary leukemia cells by survivin-specific CTLs. Primary malignant cells from HLA-A2–positive (CLL-K, AML-Ah, AML-Bu, AML-Na, ALL-Sc) or HLA-A2–negative (CLL-F, AML-Bd, AML-Ra, AML-Fi) patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL) were used as targets in a standard ⁵¹Cr-release assay.